South San Francisco, CA September 2, 2023 Press Release ALINA data demonstrate Alecensa reduces disease recurrence in the early setting for people with ALK-positive non-small cell lung cancer (NSCLC), building on its long-established benefit in the advanced setting About half…
South San Francisco, CA September 4, 2020 Submitted by Genentech Genentech Announces FDA Approval of Gavreto (pralsetinib) for the Treatment of Adults With Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer Gavreto is a once-daily, oral precision therapy that selectively inhibits…
South San Francisco, CA February 20, 2019 Genentech Press Release Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Applications (NDAs)…
South San Francisco, CA September 5, 2018 Press Release Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from its broad clinical development program across different types of lung cancer will be…
South San Francisco, CA June 30, 2018 Press Release Genentech’s TECENTRIQ in Combination with Chemotherapy Helped People with Previously-Untreated Extensive-Stage Small Cell Lung Cancer Live Significantly Longer Compared to Chemotherapy –IMpower133 is the first Phase III study with an immunotherapy-based…
South San Francisco, CA November 29, 2017 Genentech Press Release – Data will be submitted to health authorities globally, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) – SOUTH SAN FRANCISCO, CA — 2017-11-19 00:00:00 Genentech,…
South San Francisco, CA August 2, 2017 Genentech Press Release Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New…
South San Francisco, CA June 5, 2017 Genentech Press Release Phase III Study Showed Genentech’s Alecensa (Alectinib) Reduced the Risk of Disease Progression or Death by More Than Half Versus Crizotinib as First-Line Treatment in a Specific Type…
South San Francisco, CA September 1, 2016 Genentech Press Release Phase III Study Showed Genentech’s Cancer Immunotherapy TECENTRIQTM (Atezolizumab) Helped People with a Specific Type of Lung Cancer Live Significantly Longer Compared to Chemotherapy TECENTRIQ showed significant improvement…